Temasek Hedges Private Placement in Coherus BioSciences, Amgen Watches

Singapore’s Temasek Holdings plans to commit up to US$ 150 million over two tranches into Redwood City, California-based Coherus BioSciences, Inc. The reason for having two tranches is essentially for hedging regulatory risk. Temasek is betting on Coherus BioSciences which is trying to take on pharmaceutical giant Amgen. Amgen has a biosimilar called Neulasta (pegfilgrastim), which is a blockbuster therapy that helps cancer patients on chemotherapy battle infections.


[ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates